Exenatide is the first-in-class glucagon-like peptide-1 receptor agonist (GLP-1RA) and has been proved to lower blood glucose by enhancing glucose-dependent insulin secretion of β-cells in T2DM patients8–11. The gene discussed is INS; the disease is type 2 diabetes mellitus.